Filana Therapeutics, Inc. FLNA
0.48 USD -0.01 (-2.03%)
At closeNov 10, 2026, 5:23 PM EST
0.48 0.00 -0.25%
After hours · Nov 10, 5:23 PM ET
0.4756 Day range 0.5119
0.45 52-week range 3.39
- YTD
- -75.64%
- 1 year
- -84.08%
News
benzinga.com Filana Therapeutics Q3 EPS $(0.22) Beats $(0.24) Estimate Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.24) by 8.33 percent. This is unchanged from the same period last year.
benzinga.com Filana Therapeutics Announces A Study Published By Yale Researchers Of New Preclinical Research On Simufilam Examined Simufilam's Impacts In Human Cell Line To Eliminate Tuberous Sclerosis Complex 2 Gene To Model Cellular Changes Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis Complex
globenewswire.com Filana Therapeutics Announces Publication in Cells of Promising Preclinical Findings for Simufilam in TSC2-Deficient Cells Findings provide new insight into simufilam's effects on cellular stress responses and mitochondrial function New research demonstrates a 37% reduction in elevated ATF4, consistent with attenuation…
globenewswire.com Filana Therapeutics to Participate in the 2026 Maxim Growth Summit Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for the treatment of Tuberous Sclerosis Complex…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers DataMEDS AI (NASDAQ:MEDS) stock moved upwards by 39.4% to $4.42 during Thursday's pre-market session. The company's market cap stands at $10.1 million. Stablecoin Development (AMEX:SDEV)…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's after-market session. The company's market cap stands at $1.0 billion. Filana Therapeutics (NASDAQ:FLNA)…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Jaguar Health (NASDAQ:JAGX) shares moved upwards by 32.2% to $45.56 during Tuesday's after-market session. The company's market cap stands at $1.1 million. Bullfrog AI Hldgs (NASDAQ:BFRG)…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Jaguar Health (NASDAQ:JAGX) stock increased by 304.5% to $10.8 during Tuesday's regular session. The company's market cap stands at $1.1 million. Greenland Mines (NASDAQ:GRML) shares moved…
benzinga.com Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward The U.S. Food and Drug Administration (FDA) on Tuesday removed a clinical hold on the investigational new drug application for Filana Therapeutics, Inc. (NASDAQ:FLNA).
benzinga.com Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward The FDA lifted a clinical hold on Filana Therapeutics' IND application, allowing a Phase 2a trial for a TSC-related epilepsy treatment.
benzinga.com FDA Lifts Clinical Hold Form Filana Therapeutics' Investigational New Drug Application To Initiate Planned Phase 2a Trial In Participants With Tuberous Sclerosis Complex-Related Epilepsy Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis Complex
globenewswire.com Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027 Filana has engaged a leading clinical research organization, has identified clinical trial sites, and is…
gurufocus.com Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, Aug. 1
prnewswire.com Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be…
benzinga.com Filana Therapeutics Q2 EPS $(0.18) Beats $(0.23) Estimate Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.23) by 18.18 percent. This is a 80.43 percent increase over losses of…
globenewswire.com Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for…- benzinga.com Maxim Group Reinstates Buy on Filana Therapeutics, Announces $5 Price Target Maxim Group analyst Jason McCarthy reinstates Filana Therapeutics (NASDAQ:FLNA) with a Buy and announces $5 price target.
benzinga.com Filana Therapeutics Q1 EPS $(0.21) Beats $(0.23) Estimate Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.23) by 8.7 percent. This is a 56.25 percent increase over losses of…
globenewswire.com Filana Therapeutics Reports Q1 2026 Financial Results and Business Update AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for…
globenewswire.com Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII AUSTIN, Texas, May 05, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for…
defenseworld.net Zevra Therapeutics (NASDAQ:ZVRA) versus Cassava Sciences (NASDAQ:FLNA) Head-To-Head Contrast Zevra Therapeutics (NASDAQ: ZVRA - Get Free Report) and Cassava Sciences (NASDAQ: FLNA - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast…
benzinga.com Filana Therapeutics Announces Publication In Epilepsia Of Preclinical Data Showing Simufilam Attenuated Seizure Progression In Mouse Model Of Severe TSC-Related Epilepsy Study in a well-accepted mouse model of severe Tuberous Sclerosis Complex (TSC) showed that simufilam attenuated the progression of seizures in a dose-dependent mannerResults confirm and extend…